| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | -1.47 | 139.3% | 208.9% |
| Total Income | -1.47 | 139.3% | 208.9% |
| Expenditure | 16.10 | 8.3% | 20.1% |
| PBT | 11.97 | 179.1% | 186.9% |
| Net Profit | 11.97 | 178.8% | 257.5% |
| OPM | 100.00% | ||
| NPM | — | ||
| EPS | 2.96 | 178.7% | 257.4% |
Kyntra Bio Reports Q2 2026 Financial Results and Provides Business Update
14 Aug 2026 · 14 Aug, 1:42 am
Summary
Kyntra Bio reported financial results for the second quarter of 2026, with total revenue from continuing operations at $(1.5) million, a decrease from $1.3 million in the prior year's quarter. However, the company achieved a net income from continuing operations of $12.0 million, or $2.96 per share, a substantial turnaround from a net loss of $13.7 million in Q2 2025. Kyntra Bio ended the quarter with $95.7 million in cash, cash equivalents, investments, and accounts receivable, and anticipates these funds will support operations into 2028. Management expressed confidence in advancing their oncology and rare disease portfolio, with key milestones including an interim analysis for FG-3246 and the initiation of a pivotal Phase 3 trial for roxadustat, both expected in the fourth quarter of 2026.
Key Highlights
- 1
Kyntra Bio reported total revenue from continuing operations of $(1.5) million for the second quarter of 2026, compared to $1.3 million for the second quarter of 2025.
- 2
Net income from continuing operations for the second quarter of 2026 was $12.0 million, or $2.96 per share, a significant improvement from a net loss of $13.7 million, or $3.38 per share, in the prior year.
- 3
As of June 30, 2026, Kyntra Bio held $95.7 million in cash, cash equivalents, investments, and accounts receivable.
- 4
The company expects its current financial resources to be sufficient to fund operating plans into 2028.
- 5
Enrollment in the Phase 2 monotherapy trial of FG-3246 continues, with an interim analysis anticipated in the fourth quarter of 2026.
- 6
The Phase 3 protocol for roxadustat in LR-MDS has been finalized, with the registrational study targeted to initiate in the fourth quarter of 2026.
- 7
Additional data from the Phase 3 MATTERHORN study were presented at the EHA Congress 2026, showing improvements in transfusion independence.
Management Comments
Thane Wettig
We continue to make progress across our oncology and rare disease portfolio and remain laser-focused on advancing toward our goal of initiating a pivotal Phase 3 trial of roxadustat in LR-MDS in the fourth quarter of this year and conducting an interim analysis of the Phase 2 trial of FG-3246 in mCRPC, also in the fourth quarter of this year. We believe we have the substrate that will enable us to create significant value for patients and stakeholders as we advance our pipeline and look forward to providing additional updates in the coming months.
Informational and educational content only. Not investment advice.